Back

Early versus late T1 infarct core following reperfusion treatment in patients presenting with acute myocardial infarction

4 May 2019 (08:47 - 08:55)
Organised by:
Congress Presentation Part of: Rapid Fire Abstract 5: late gadolinium enhancement Myocardial Disease EACVI Premium Access EuroCMR 2019

About the speaker

Photo
Doctor Alessandra Borlotti

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Prevalence and correlates of mid-wall late gadolinium enhancement in patients with ischemic cardiomyopathy
Doctor Z. Tsoumani (London, GB)
Abstract Slides Video
Presentation thumbnail
Predictors of CMR confirmed microvascular damage after successfully reperfused STEMI.
Doctor R. Aguilar Torres (Madrid, ES)
Abstract
Presentation thumbnail
Comparison of signal intensity ratio, diagnostic accuracy, transmurality and image quality between dark blood lge and bright blood lge in patients with ischemic cardiomyopathy
Doctor G. Muscogiuri (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Persistently increased inflammatory status in the first days post MI is associated with larger myocardial scar, higher transmurality extent and deterioration of ventricular function at 1 month
Doctor A. Mester (Oradea, RO)
Abstract Slides Video
Presentation thumbnail
Diagnostic accuracy of single-shot two-dimensional multisegment late gadolinium enhancement in ischemic and non-ischemic cardiomyopathy
Doctor G. Muscogiuri (Bergamo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire Abstract 5: late gadolinium enhancement

The Event

Event poster

EuroCMR 2019

4 May 2019 08:47 CET
You may be interested in
thumbnail
Congress Session
Advanced imaging in heart failure
thumbnail
Congress Session
Ventricular arrhythmias and prevention of sudden cardiac death (1)
thumbnail
Webinar
The role of cardiac magnetic resonance for patients with ventricular arrhythmias and the prevention of sudden cardiac death in light of the 2022 ESC Guidelines

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources